7.2. rationale follow-up. oncological perspective, surveillance important early detection recurrence may increase likelihood curative treatment. studies suggest local recurrence significantly reduce long-term survival successfully treated . however, recent multi-centre study reported increased risk recurrence following glansectomy men aggressive disease (t3 and/or high grade), turn resulted poorer os css . disease spread inguinal lns greatly reduces rate long-term css. follow-up also important survivorship, allowing detection management physical psychological impact treatments. use patient reported outcome measures (proms) related body image (male genital self-image scale mgsis-5) lymphoedema (groin lower limb lymphoedema questionnaire g3l-20) proposed tools help patients healthcare team raise discuss embarrassing topics consultations . local regional nodal recurrences usually occur within two three years primary treatment . recent study 509 patients reported 52.3% local recurrences occurred within two years 79.5% within three years . fewer 5% regional distant recurrences occur two years, majority occurring within first year treatment . five years, recurrences either local new primary lesions . supports intensive follow-up regimen first two years, less intensive follow-up later total least five years. follow-up five years may omitted motivated patients undertake regular self-examination reliably . 7.2.1. follow-up local treatment negative inguinal nodes, follow-up include physical examination penis groins local and/or regional recurrence. additional imaging proven benefit. follow-up also depends primary treatment modality. histology glans obtained confirm disease-free status following laser ablation topical chemotherapy. potentially curative treatment inguinal nodal metastases, ct mri imaging detection systemic disease (imaging thorax, abdomen pelvis) performed 3-monthly intervals first two years. following this, frequency usually reduced 6-monthly total 5 years follow-up. however, one study 224 node-positive patients reported two recurrences years 3–5 follow-up, pn3 patients . although rare, late local recurrence may occur. therefore, regular follow-up stopped 5 years, provided patient understands need report local changes immediately . patients unlikely self-examine, long-term follow-up may necessary (table 7.1). 7.2.2. recurrence primary tumour local recurrence likely types local organ-sparing treatment. recently believed influence css rate, although one study recently challenged showing reduction os css following local recurrence glansectomy . large series glansectomies reported local recurrence rates around 10% , although others reported recurrence 27% patients treated penis-preserving modalities, usually occurring within first two years . partial penectomy, risk local recurrence 4–5% . local recurrence easily detected physical examination, patient physician. patient education essential part follow-up, patient urged visit specialist changes seen. 7.2.3. regional recurrence regional recurrences occur first two years treatment, irrespective whether surveillance invasive nodal staging used. although unlikely, regional recurrence occur later two years treatment. therefore advisable continue follow patients . highest rate regional recurrence (9%) occurs patients managed surveillance, lowest patients undergone invasive nodal staging modified ilnd dsnb whose lns negative (2.3%). use us fnac suspicious cases improved early detection rate regional recurrence . patients surgery ln metastases without adjuvant treatment increased risk regional recurrence 19% . regional recurrence requires timely treatment rilnd (neo)adjuvant chemotherapy/chemo-radiotherapy. table 7.1: follow-up regime penile cancer interval surveillanceexaminations investigationsminimum duration follow-upyears 1–2years 3–5recommendations follow-up primary tumourpenile-preserving treatment3-monthly6-monthlyregular physician self-examination. repeat biopsy topical laser treatment pein (optional).5 yearsamputation3-monthlyannuallyregular physician self-examination.5 yearsrecommendations follow-up inguinal lymph nodessurveillance3-monthly6-monthlyregular physician self-examination.us ± fnac optional.5 yearspn03-monthlyannuallyregular physician self-examination.us ± fnac optional.5 yearspn+3-monthly6-monthlyregular physician self-examination.us ± fnac, ct chest/abdomen/pelvis 18fdg-pet/ct optional.5 years ct = computed tomography; 18fdg = 18f-fluoro-2-deoxy-d-glucose; fnac = fine needle aspiration cytology;pet = positron emission tomography; us = ultrasound.